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vABSTRACT
Human neutrophils (PMN cells) contain four peptides known as alpha (α)-
defensins or HNP 1-4.  The peptides have broad-spectrum antibiotic activity.
HNP 1-3 are major neutrophil components.  They differ by only one amino acid
residue.  HNP-4 is found in small amounts, and has a different sequence.  HNP-4
purified from neutrophils was reported to be 100-times more active than HNP-1
against Escherichia coli, suggesting that HNP-4 plays a special role in helping
neutrophils kill gram-negative bacteria.
Activity of HNP-4 against gram-negative bacteria is of special interest because
Aggregatibacter (Actinobacillus) actinomycetemcomitans (A.a.) and other
periodontal pathogens are gram-negative.  These bacteria are resistant to HNP 1-3.
Defensin-resistance may contribute to the ability of these bacteria to cause disease.
There have been no studies of HNP-4 activity against oral bacteria, because HNP-4 is
found in small amounts and is difficult to purify.  Recently, HNP-4 was chemically
synthesized, making it possible to study its antibacterial activity.  However, synthetic
HNP-4 was reported to be no more active than HNP-1 against E. coli.
Lipopolysaccharide (LPS) covers the surface of gram-negative bacteria.  Each
LPS molecule has three parts: a long carbohydrate chain (oligosaccharide) that is
exposed on the cell surface, a short carbohydrate core, and lipid A that anchors LPS
in the outer membrane.  LPS on the bacterial cell surface may be the receptor for
HNP-4 and other peptides that kill gram-negative bacteria.
Our aims were to: (1) Compare the purity and physical properties of purified and
synthetic HNP-4. (2) Compare activity of synthetic and purified HNP-4 against
E. coli. (3) Determine whether synthetic HNP-4 binds to purified E. coli LPS. (4)
Locate the HNP-4 binding site for synthetic HNP-4 on E. coli LPS molecules. (5)
Measure activity of synthetic HNP-4 against A.a. (6) Compare binding of synthetic
HNP-4 to LPS purified from E. coli and A.a.
Results: (1) Purified and synthetic HNP-4 were of high purity.  They had the same
molecular mass, which was equal to the mass calculated from the amino acid
sequence. (2) Activity of purified and synthetic HNP-4 against E. coli was the same,
and similar to the activity of HNP-1. (3) LPS purified from E. coli absorbed synthetic
HNP-4. (4) Experiments with LPS fragments showed that synthetic HNP-4 was
absorbed to the LPS inner core. (5) Synthetic HNP-4 partially inhibited growth of
A.a. but did not kill these bacteria. (6) There was no difference in the ability of
E. coli or A.a. LPS to absorb synthetic HNP-4.
The results suggest that HNP-4 is not more active than other neutrophil alpha-
defensins against gram-negative bacteria.  The results also indicate that LPS on the
surface of gram-negative bacteria could be the receptor for HNP-4.  Because HNP-4
binds to the LPS inner core, HNP-4 may help neutrophils kill gram-negative bacteria
that lack oligosaccharide and the LPS outer core.
The periodontal pathogen A.a. is resistant to all of the human leukocyte alpha-
defensins including HNP-4.  Therefore, synthetic HNP-4 is not likely to be used in
dental practice to prevent or treat oral disease.  Resistance of A.a. to HNP-4 is not the
result of a difference in LPS structure that interferes with HNP-4 binding.  Further
studies are needed to determine the mechanism of defensin resistance.
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1CHAPTER 1.  INTRODUCTION AND LITERATURE REVIEW
Human Leukocyte Defensins
Neutrophils (PMN leukocytes) are the first line of defense against infection.
Neutrophils are the most abundant leukocytes in blood and make up about 50% of
circulating leukocytes.  Neutrophils are the first cells to respond to infection. They
leave the bloodstream and migrate through the blood vessel walls and into the tissues
in response to chemical signals released at sites of infection and inflammation.
Numbers of neutrophils are high in oral tissues.  They migrate into the oral tissues
and are shed into the oral cavity at the gingival crevices (1,2).  The number of
neutrophils in oral tissues increases greatly in patients with gingivitis and
periodontitis (3).
Neutrophils are phagocytic cells.  In the process of phagocytosis, neutrophils
ingest micro-organisms and kill them in cell compartments called phagosomes.
Neutrophils have two general mechanisms for killing micro-organisms (4).  In
oxidative killing, neutrophils produce superoxide anions and other oxidizing agents
that kill micro-organisms by oxidizing essential cellular components.  Neutrophils
also contain high levels of antimicrobial enzymes such as lysozyme and other
peptides and proteins with antimicrobial activity.  These antimicrobial agents kill
micro-organisms by non-oxidative mechanisms, such as by making microbial cell
membranes leaky.
One class of non-oxidative antimicrobial agents found in neutrophils is a family
of peptides known as alpha (α)-defensins (5-7).  These peptides have broad-spectrum
antibiotic activity.  They are able to kill fungi and gram-negative and gram-positive
bacteria.  Alpha-defensins are major neutrophil components, making up 5 to 7% of
the total amount of protein in the cell (8).
Alpha-defensins are stored in secretory granules in the cytoplasm.  They are
released from the granules into phagosomes after the neutrophils phagocytize micro-
organisms.  Alpha-defensins are also released from neutrophils into the environment
outside the neutrophil when the cells are stimulated or during cell lysis.  Alpha-
defensins have been detected in gingival crevicular fluid (9-10).
Human leukocyte alpha-defensins are examples of cationic antimicrobial peptides
(CAPs), which are widely distributed in nature (11-13).  Defensins are members of
the family of cysteine-rich CAPs, which are found not only in vertebrates but in
plants and insects (14-16).  Alpha-defensins have a unique structure that differs from
other defensins, and are found only in primates, rodents, and rabbits (7).
Three alpha-defensin peptides were isolated from human neutrophils (17) and
named HNP (Human Neutrophil Peptide) 1-3 (Figure 1.1).  The peptides are
Figure 1.1.  Amino acid sequences of human leukocyte alpha-defensins.
Amino acid residues that differ between the 4 peptides are shown in black.  Residues
that are the same are shown in gray.
2
arginine (R)-rich, which gives them a net positive (cationic) charge.  They have 6 cysteine
(C) residues (numbered 1-6 from the N-terminus), which form 3 intramolecular disulfide
bonds.  The disulfide bonds are from cysteine residues 1 to 6, 2 to 4, and 3 to 5.  This
arrangement of disulfide bonds is the unique structural feature of alpha-defensins (18).
HNP 1-3 have 30, 29, and 30 amino acid residues and molecular weights of 3442,
3371, and 3486, respectively.  The three peptides differ by only one amino acid residue
at the N-terminus.  At neutral pH, the three peptides have a net positive charge of +3.
Most studies on human alpha-defensins have used HNP-1 or a mixture of HNP 1-3.
Later, a fourth human leukocyte alpha-defensin was discovered in human
neutrophils (19) and was named HNP-4.  Neutrophils have small amounts of HNP-4,
only about 1% the amount of HNP 1-3.  Figure 1.1 shows that the structure of HNP-4
is different from the structures of HNP 1-3.  HNP-4 is arginine-rich, has 6 cysteine
residues in the same positions as in HNP 1-3, and has 3 disulfide bonds that are
linked the same way.  On the other hand, the amino acid sequence of HNP-4 is
longer, and many of the amino acids are different from those in HNP 1-3.  It has 33
amino residues, and 19 of the first 30 amino residues are different from those in
HNP-1.  The molecular weight of HNP-4 is 3710, and the peptide has a net charge of
+4 at neutral pH.
The differences between HNP-4 and HNP 1-3 could indicate that HNP-4 has a
special role in neutrophils.  Purified HNP-4 was reported to be similar to HNP-1 in
activity against gram-positive bacteria and fungi in vitro (19).  However, purified
HNP-4 was 100-times more bactericidal than HNP-1 when tested against a strain of
the gram-negative bacterium Escherichia coli (E. coli).  These results could indicate
R I P A C I A G E R R Y G T C I Y Q G R L W A F C CCYCA
R I P A C I A G E R R Y G T C I Y Q G R L W A F C CCYC
R I P A C I A G E R R Y G T C I Y Q G R L W A F C CCYCD
R L V F C R R T E L R V G N C L I G G V S F T Y C CCSCV T R V
HNP-1
HNP-2
HNP-3
HNP-4
5 10 15 20 15 30
3that HNP-4 is especially important in the killing of gram-negative bacteria by
neutrophils.
HNP-4 is present in small amounts in neutrophils and is difficult to purify.
Therefore, there have been few studies on HNP-4 antimicrobial activity.  Recently,
HNP-4 was chemically synthesized (20).  The amino acid sequence was verified by
chemical sequencing. The disulfide-bonding pattern was determined using X-ray
crystallography and found to be the same as in purified HNP-4 (21).
The availability of synthetic HNP-4 makes it possible to study HNP-4
antimicrobial activity in vitro.  However, synthetic HNP-4 was reported to be similar
to HNP-1 in bactericidal activity against E. coli (20).  Therefore, there is a conflict in
the scientific literature about the antimicrobial activity of HNP-4.  On the other hand,
the study with purified HNP-4 and the study with synthetic HNP-4 used different
assay methods and different strains of E. coli.  These differences may account for
differences in results.
Periodontal Pathogens and Defensins
Periodontal pathogens are types of bacteria that are associated with periodontal
disease (22-25).  These bacteria are often found in sub-gingival plaque and in
periodontal pockets.  Many of these periodontal pathogens are gram-negative
anaerobic bacteria such as Aggregatibacter (Actinobacillus) actinomycetemcomitans
(A.a.), Porphyromonas gingivalis (P.g.), Prevotella intermedia (P.i.), and
Fusobacterium nucleatum (F.n.).  These gram-negative periodontal pathogens are
resistant in vitro to human leukocyte alpha-defensins (HNP-1 or a mixture of
HNP 1-3) (26,27).  Resistance to neutrophil alpha-defensins may be important in the
ability of these bacteria to cause disease.  The bacteria survive and grow in an
environment where there are high numbers of neutrophils.
Periodontal pathogens are not resistant to all cationic antimicrobial peptides.  For
example, they are killed by NP-1, a potent alpha-defensin from rabbit neutrophils
(28).  They are also killed by protegrins (29,30), which are cysteine-rich CAPs from
porcine neutrophils.  Purified protegrins are undergoing clinical trials as possible oral
therapeutic agents (31,32).
If HNP-4 is especially effective in killing gram-negative bacteria including
periodontal pathogens, then synthetic HNP-4 might be effective in vivo to prevent or
treat periodontal disease.  Resistance of periodontal pathogens to HNP-4 has not been
studied.  Studies may show that periodontal pathogens are resistant to all human
alpha-defensins including HNP-4.  If they weren’t resistant, then they wouldn’t be
able to survive in sub-gingival plaque and periodontal pockets and wouldn’t be able
to cause disease.
It’s also possible that the bacteria are resistant to HNP 1-3, but not to HNP-4.
The amount of HNP-4 in human neutrophils may be too small to kill or block growth
of bacteria in vivo.  Therefore, the bacteria may be able to survive in vivo, even
though they would be killed if they were exposed to higher concentrations of HNP-4.
Lipopolysaccharide and Gram-negative Bacteria
Gram-negative bacteria have two unique features.  The first is that each cell is
surrounded by two membranes. The cell envelope consists of an outer membrane and
an inner membrane, with a layer of peptidoglycan in between (Figure 1.2).  The
presence of lipopolysaccharide (LPS) is the other unique feature of gram-negative
bacteria.  The outer layer of the outer membrane consists largely of LPS (Figure 1.3).
Each cell is covered with about two million molecules of LPS (33).
Besides LPS, a few other substances are exposed on the bacterial cell surface
(34). Exposed components include outer membrane proteins, structures such as
flagella for motility, pili for DNA transfer, and fimbria for attachment.  Some bacteria
have an additional S (slime) layer that covers LPS and the cell surface.
LPS is the receptor on the bacterial cell surface for some antimicrobial proteins
and peptides.  BPI (Bactericidal Permeability Inducing Factor) is a small cationic
antimicrobial protein from human neutrophils that binds to LPS and kills many gram-
negative bacteria (35).  Polymyxin B is an antibiotic produced by the gram-positive
bacteria Bacillus polymyxa (36,37).  It is a cationic peptide with a lipid attached.
Polymyxin B binds to the hydrophobic part of LPS and kills only gram-negative
bacteria.
LPS molecules consist of three parts (33,38): oligosaccharide, core, and lipid A
(Figure 1.4).  Oligosaccharide is the most exposed part of the LPS on the cell surface.
It is responsible for the immune response against specific strains of gram-negative
bacteria.  Therefore, it is often referred to as the O antigen.  Oligosaccharide is a long
polymer of 6-carbon sugars (hexoses) with short hexose branches in a repeating
pattern.
The core has two parts: outer and inner core.  The outer core is a short polymer of
hexoses and a 7-carbon sugar (heptose).  The inner core is a polymer containing
heptose and the 8-carbon sugar Kdo (3-deoxy-D-manno-octulosonic acid, also known
as 2-keto-3-deoxyoctonoic acid).  Kdo is found only in LPS.  The inner core of LPS
can also have phosphate, phosphoryl-ethanolamine, and diphosphoryl-ethanolamine
groups.
Lipid A is hydrophobic and holds the LPS molecule in the hydrophobic layer of
the outer membrane.  Lipid A has two glucosamines, two phosphate groups, and
usually six fatty acids.  Four of the fatty acids are linked to the glucosamines, and
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Figure 1.2.  Cut-away diagram of a gram-negative bacterium.
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Figure 1.4.  Structures of LPS and the deacyl-LPS and lipid A fragments.
Sugars are represented by hexagons, phosphate groups by P, and fatty acids by
pleated lines.
P
P
Lipid A
two are linked to hydroxyl groups on beta-hydroxy fatty acids (myristic acid).  Lipid
A is the part of LPS that has endotoxin activity, which causes fever and septic shock.
Different strains of bacteria can have differences in all three parts of the LPS
molecule.  For example, there are six known serotypes (a through f) of A.a.  These
serotypes differ in the structure of the oligosaccharide part of LPS.  The repeating
unit in the oligosaccharide part of LPS of each of the six strains has been determined
(39-41).
Some bacteria lack the oligosaccharide part of LPS.  Examples are the K12 strains
of E. coli.  Bacteria that lack oligosaccharide have a “rough” colony morphology that
differs from the “smooth” morphology of most gram-negative bacteria.  Rough
strains are more sensitive than smooth strains to killing by polymyxin B (42),
probably because it is easier for polymyxin to enter the LPS layer and bind to lipid A
when there is no oligosaccharide.  A K12 strain of E. coli was used in the study by
Wilde et al. (19), which reported that purified HNP-4 was especially effective against
E. coli.
The structure of the core has been determined for K12 strains of E. coli. (Figure
1.5).  Differences in the core structure have been reported for other strains of E. coli
and salmonella strains.  For example, some strains lack the third Kdo unit.  However,
the inner core structure shown in Figure 1.5 is highly conserved in enteric bacteria
(33,38).
The structure of the lipid A part of LPS has been determined for many types of
gram-negative bacteria because lipid A is the part of LPS that has immunoregulatory
activity and endotoxin activity (33).  There is only a small difference in the lipid A of
E. coli and A.a.  The E. coli lipid A has five 14-carbon fatty acids and one 12-carbon
fatty acid.  The A.a. LPS has six 14-carbon fatty acids (43).
Some periodontal pathogens such as P.g. and P.i. have lipid A structures that are
different from the lipid A of A.a. or E. coli (44, 45).  The lipid A part of LPS
preparations from these organisms have one rather than two phosphates.  They have
only three or five fatty acids, and some of the fatty acids have methyl branches.  The
LPS or lipid A from these organisms has less endotoxin activity, probably as a result
of these differences in structure (46, 47).
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Figure 1.5.  Structures of E. coli LPS and LPS from rough (R) mutants.
Oligosaccharide is a polymer of hexoses.  The outer core contains the hexoses
glucose (Glc), galactose (Gal), and N-acetyl-glucosamine (GlcNac), and a heptose
(Hep).  The inner core contains heptose (Hep) and Kdo with phosphate (P) and
phosphoryl- or pyrophosphoryl-ethanolamine (P-Etn or PP-Etn).  The structure of
lipid A is shown in Figure 1.4.
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CHAPTER 2.  SPECIFIC OBJECTIVES
The general objectives are to determine: (a) Whether HNP-4 differs from the
other human neutrophil alpha-defensins in killing gram-negative bacteria including
E. coli and the periodontal pathogen A.a. (b) Whether LPS on the surface of gram-
negative bacteria could be the receptor that binds HNP-4.
The first objective is to use mass spectrometry to compare the purity and physical
properties of synthetic HNP-4 and HNP-4 purified from human leukocytes.  The aim
is to determine whether there are any differences between synthetic and purified
HNP-4 that could cause them to have different antimicrobial activity.
The second objective is to compare the antibacterial activity of synthetic and
purified HNP-4 against the standard test organism E. coli ML-35 under standard
assay conditions.  The aims are to determine if there is any difference in antibacterial
activity of synthetic and purified HNP-4 and whether HNP-4 is especially effective in
killing gram-negative bacteria.
The third objective is to determine whether HNP-4 binds to purified LPS from
E. coli.  Purified LPS will be added to mixtures of HNP-4 and E. coli ML-35 to
determine whether the purified LPS absorbs HNP-4 and blocks killing of E. coli.
If purified LPS blocks killing, then blocking gives an indirect method of measuring
binding of HNP-4 to LPS.  The aim is to determine whether HNP-4 binds to LPS.
If so, this result could indicate that LPS is the receptor for HNP-4 on the cell surface
of gram-negative bacteria.
The fourth objective is to compare the binding of HNP-4 to LPS fragments.  If the
results show that LPS could be the receptor for HNP-4 on the cell surface, LPS
fragments that lack parts of the complete LPS structure will be added to mixtures of
HNP-4 and E. coli ML-35 to determine whether the fragments absorb HNP-4 and
block killing of E. coli.  The aim is to identify the part of the LPS molecule that acts
as the receptor for HNP-4.  If the results indicate that HNP-4 binds to
oligosaccharide, then HNP-4 may bind better to oligosaccharides that have a
particular arrangement of hexoses. Therefore, killing of A.a. and other pathogens may
be strain-specific.  If the results indicate that HNP-4 binds to the core, HNP-4 may be
more effective against “rough” strains without oligosaccharide than against “smooth”
strains.  If the results indicate that HNP-4 binds to lipid A, then differences in the
lipid A structures of periodontal pathogens might make HNP-4 able to kill some types
of periodontal pathogens but not others.
The fifth objective is to measure the antibacterial activity of HNP-4 against the
periodontal pathogen A.a. in vitro.  The aim is to determine whether A.a. is resistant
to all the human leukocyte alpha-defensins or whether HNP-4 is more effective than
HNP 1-3 against this gram-negative periodontal pathogen.
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The sixth objective is to compare the binding of HNP-4 to LPS purified from
E. coli and from A.a.  Various amounts of E. coli or A.a. LPS will be added to
mixtures of HNP-4 and E. coli ML-35 to determine whether the purified LPS absorbs
HNP-4 and blocks killing of E. coli.  This will give an indirect method of comparing
binding of HNP-4 to the two types of LPS.  The aim is to determine whether there is
a difference in binding of HNP-4 to LPS from E. coli or A.a.  If LPS is the receptor
for HNP-4, and HNP-4 kills both E. coli and A.a., then HNP-4 should bind to
purified LPS from E. coli or A.a.  On the other hand, if A.a. is resistant to HNP-4,
then HNP-4 may bind to E. coli LPS but not to A.a. LPS.
CHAPTER 3.  MATERIALS AND METHODS
Materials
Chemicals
Bovine serum albumin, trifluoroacetic acid (TFA), acetonitrile, and sinapinic acid
were from Sigma Aldrich Chemical Co., St. Louis, MO.  Sodium bicarbonate,
triethylamine, and hydrochloric acid were from Fisher Scientific, Pittsburgh, PA.  All-
in-1 peptide and protein standards were from Ciphergen Biosystems, Freemont, CA.
Bacto-agar and Trypticase Soy Broth (TSB) were from Becton Dickinson, Sparks, MD.
Antimicrobial Peptides
Polymyxin B was from Sigma Aldrich Chemical Co.
HNP-4 and a mixture of HNP 1-3 were purified from a 10% acetic acid extract of
human neutrophil granules by modifications of the methods of Wilde et al. (19) and
Ganz et al. (17) in the laboratory of Dr. Thomas at the UTHSC College of Dentistry.
The yields of purified HNP-4 and HNP 1-3 from 200 mg of granule protein were 0.17
mg and 13.7 mg, respectively, or 0.1 % and 7 %.
HNP-1 was purified from the mixture of HNP 1-3 by the method of Ganz et al.
(17) in the laboratory of Dr. Thomas at the UTHSC College of Dentistry.  The protein
concentrations of purified HNP-1 and HNP-4 were determined by the method of
Lowry et al. (48) with bovine serum albumin as the standard.
Synthetic HNP-4 (20) was provided by Dr. W. Lu at the University of Maryland
Biotechnology Institute.  Synthetic HNP-4 (1.67 mg) was dissolved in 1.5 mL 0.01%
acetic acid to give a 300 µM solution, assuming a molecular weight of 3710.  The
300 µM synthetic HNP-4 solution was assayed using the protein determination
method of Lowry et al. (48) with bovine serum albumin as the standard and was
found to give the expected concentration.  Solutions of 100 µM HNP-4 and 10 µM
HNP-4 were prepared by dilution of the 300 µM solution in 0.01% acetic acid.
LPS and LPS Fragments
LPS from E. coli of serotype O111:B4 was purchased from List Biological
Laboratories, Campbell, CA.  Rough LPS (Ra) from E. coli EH100 was purchased
from Sigma Aldrich Chemical Co.  Rough LPS (Rc) from E. coli J5 and rough LPS
(Re) from E. coli K12-D31m4 were purchased from List Biological Laboratories.
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A.a. LPS was purified from the Y4 strain in the laboratory of Dr. Jegdish Babu at the
UTHSC College of Dentistry using the method of Millar et al. (49) in which LPS is
extracted from an outer membrane fraction (50) by the hot water-phenol method of
Westphal and Jann (51).
Deacylated (detoxified) LPS (deacyl-LPS), prepared by alkaline hydrolysis (52) of
LPS from E. coli serotype O111:B4, was purchased from Sigma Aldrich Chemical
Co.  Lipid A (diphosphoryl) prepared (53) from LPS of the rough (Re) mutant E. coli
K12-D31m4 was purchased from List Biological Laboratories Inc.  Kdo2-lipid A
(Di[3-deoxy-D-manno-octulosonyl]-lipid A) (ammonium salt) was purchased from
Avanti Polar Lipids Inc., Alabaster, AL.
LPS, deacyl-LPS and Kdo2-lipid A were dispersed in water or 10 mM potassium
phosphate pH 7.4 buffer by incubating 5 min in a sonicator bath at 25°C.  Lipid A
was solubilized with triethylamine by the procedure of Tanamoto et al. (54).
Bacteria
E. coli of serotype O111:B4, a smooth strain with well-characterized LPS, was
obtained from Dr. Peter G. Eichaker and Dr. Steven Richmond at the Critical Care
Medicine Department of the National Institutes of Health, Bethesda, MD.  All other
bacterial strains were obtained from the American Type Culture Collection (ATCC),
Manassas, VA.  E. coli ML-35 (ATCC 43827) was used as the standard test organism for
measuring defensin activity.  E. coli J5 (ATCC 43745) is a rough (Rc) mutant that lacks
oligosaccharide and most of the core.  The Y4 strain of A.a. (ATCC 43718) is serotype b.
Methods
Bacterial Inocula
E. coli ML-35 bacteria were grown to early stationary phase in Medium A-
Glucose (0.06 M potassium phosphate, 1.7 mM sodium citrate, 7.6 mM ammonium
sulfate, 0.014 mM magnesium sulfate, 20 mM glucose) (55).  All other bacteria were
grown as indicated below in filter-sterilized Trypticase Soy Broth (TSB).  Portions
(1.5 mL) of the bacterial cultures were frozen at -80°C.  The frozen cultures were
used to inoculate cultures for experiments.
Bacterial Cultures
An inoculum was thawed and a 1 mL portion was added to 100 mL of TSB.
E. coli strains were grown for 16 h to stationary phase in foam-stoppered flasks at
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37°C with continuous mixing for aeration in an rotary shaker.  A.a. Y4 was grown for
24 h to stationary phase at 37°C with continuous mixing in sealed 100 mL bottles to
restrict aeration. Media for both liquid and solid cultures of A.a. were sterilized by
ultrafiltration through 0.4 μ nitrocellulose filters (Nalgene Co., Rochester, NY).
Media for liquid cultures of E. coli were sterilized by ultrafiltration, and media for
solid-phase culture of E. coli were sterilized by autoclaving.
For experiments with E. coli, the bacteria in a 10 mL portion of a stationary phase
culture were collected and washed twice by centrifugation at 17,000 x g for 12 min at
4°C with 10 mM potassium phosphate pH 7.4 buffer.  The washed bacteria were
suspended in 10 mM potassium phosphate buffer to an optical density of 0.6 at 600
nm to give 2 x 108 colony forming units (CFU)/mL.
For experiments with A.a., a portion of a 24 h culture was diluted 5 fold to 1 x
108 CFU/mL with 10 mM phosphate buffer at 25°C and used immediately.
Antibacterial Assay
Bacteria (106 CFU/mL) in 100 µL total volume (E. coli) or 200 µL total volume
(A.a.) were incubated with gentle mixing in 1% TSB with 10 mM potassium
phosphate pH 7.4 buffer.  Antimicrobial peptides and LPS were added in various
concentrations as indicated for each experiment.  Incubation mixtures with E. coli
were incubated 4 h at 37°C aerobically in 1.8 mL polypropylene vials.  Incubation
mixtures with A.a. were incubated 4 h at 37°C in a 96-well plate that was placed
inside a BBL™ GasPak Pouch™ Anaerobic System to lower the oxygen (O2)
concentration and raise the carbon dioxide (CO2) concentration.  At the end of the
incubation, the number of viable bacteria was determined by making serial 1:10
dilutions in sterile 10 mM phosphate pH 7.4 buffer, plating 0.8 mL portions of the
dilutions on solid growth medium (TSB/2% agar), and counting bacterial colonies
after 1 to 2 days at 37°C.  E. coli bacteria on solid media were incubated under air at
37°C.  A.a. bacteria on solid media were incubated under 95% air/5% CO2 at 37°C.
The number of viable bacteria/mL in the incubation mixture was calculated.
MALDI-TOF Mass Spectrometry
MALDI-TOF mass spectrometry was used to compare the molecular weight of
synthetic and purified HNP-4 and to evaluate the purity of the preparations.  Mass
spectra in the range of 2,000 to 10,000 were obtained with a Ciphergen Biosystem
PBSII mass spectrometer calibrated with All-in-1 peptide standard.  Standards and
samples were mixed 1:1 with a saturated sinapinic acid solution in 50% acetonitrile
with 0.5% TFA.  Each sample (1 µL) was applied to two positions on a gold metal
chip (Ciphergen Biosystems).  Synthetic HNP-4 was applied at 25 pmoles per spot.
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Samples were air-dried, and mass spectra were obtained.  Average spectra were
obtained from 80 laser shots at 20 positions distributed across the sample.
Mass spectra of the samples were also obtained in the molecular weight range
from 10,000 to 100,000 Da with the PBSII mass spectrometer calibrated with All-in-1
protein standard.
Estimated Molecular Weights of LPS and Fragments
Molecular weights were estimated or calculated for LPS and LPS fragments so
that the number of molecules needed to block killing by HNP-4 could be determined.
Molecular weights used to calculate concentrations of LPS preparations are listed in
Table 3.1.
All LPS preparations are heterogeneous due to variation in the number of
repeating units in the oligosaccharide part and varying amounts of substitution on
heptose and Kdo units in the core.  An average molecular weight of 10,000 Da was
reported for LPS of E. coli serotype O111:B4 (56) and was used in calculations in
this study.  Because no estimates for the molecular weight of LPS from the A.a. Y4
strain were found, the same value of 10,000 Da was used.
Figure 1.4 shows schematic representations of the structure of LPS, deacyl LPS,
and lipid A fragments.  Based on the structure, a molecular weight of 8,704 was
calculated for deacylated LPS.  The molecular weights of one 12-carbon fatty acid
[200], one 14-carbon fatty acid [228], and four 14-carbon beta-hydroxy fatty acids [4
x 244] were subtracted from 10,000, and the molecular weight of 6 water molecules
[6 x 18] was added.
Diagrams of the structures of LPS from rough mutants of E. coli K12 strains are
shown in Figure 1.5. A molecular weight of 4,442 was calculated for E. coli Ra LPS
from the molecular weight of 2,663 calculated for the structure of the K12 core
(33,38) plus the molecular weight of 1,797 that was calculated for the structure of
E. coli lipid A, minus the molecular weight of one water molecule.  Molecular
weights of 3,733 and 2,660 were calculated for E. coli Rc and Re LPS from the
structures shown in Figure 1.5.
Data Analysis
All experiments were performed at least twice with duplicate samples.  Statistical
significance was evaluated by Analysis of Variance (ANOVA) followed by Scheffe’s f
test to calculate p values using StatView 5.0 software.  Values less than 0.05 were
considered significant.
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Table 3.1.  Average molecular weights of LPS preparations.
LPS preparation     Average molecular weight (Da)
LPS from E. coli of serotype O111:B4 10,000
LPS from A.a. Y4 (serotype b) 10,000
Deacyl-LPS from E. coli of serotype O111:B4   8,704
Ra LPS from E. coli EH100   4,442
Rc LPS from E. coli J5   3,733
Re LPS from E. coli K12-D31m4   2,660
Kdo2-lipid A (ammonium salt)   2,307
Diphosphoryl lipid A   1,797
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CHAPTER 4.  RESULTS
Physical Properties of Synthetic and Purified HNP-4
MALDI-TOF Mass Spectrometry
The goals of these experiments were to determine whether there are any
differences between synthetic HNP-4 and purified HNP-4 that could cause them to
have different antimicrobial activity.  MALDI-TOF mass spectrometry was used to
compare the molecular weights of synthetic and purified HNP-4 and to evaluate the
purity of the synthetic and purified HNP-4 preparations.
Mass spectra of the Ciphergen All-in-1 standards, synthetic HNP-4, and purified
HNP-4 were measured in the range of 2,000 to 10,000 Da (Figure 4.1).  The first
spectrum in Figure 4.1 is that of the All-in-1 peptide standard. The instrument was
calibrated using the masses of 3469, 5808, and 7034 Da for bovine insulin B chain,
human insulin A+B chains, and hirudin BHVK. The second and third spectra in
Figure 4.1 are of purified and synthetic HNP-4.  Purified and synthetic HNP-4 each
had a single major peak at 3711 Da.  The purified HNP-4 preparation contained a
very minor contaminant with a mass of 4396 Da.
Minor peaks below and above the major peak were seen with both synthetic and
purified HNP-4.  These minor peaks are often seen in mass spectra of peptides when
sinapinic acid is used as the energy absorbing matrix.  A small peak was visible in
both preparations at 7422 Da, twice the molecular weight of the HNP-4, and is
probably a dimer of HNP-4.
Figure 4.2 shows the mass spectra expanded to show only the 3400 to 3800 Da
range, the region of the HNP-4 peak. The purified and synthetic HNP-4 preparations
each had peaks at 3711 Da. The calculated molecular mass for HNP-4 is 3710 Da.
The calculated and observed values are identical within the instrument accuracy of
0.1% for externally calibrated samples.
Mass spectra of the samples were also obtained in the molecular weight range
from 10,000 to 100,000 Da (not shown).  No proteins were detected.
These results indicate that there was no difference in the molecular mass of the
synthetic and purified HNP-4 and that the synthetic and purified HNP-4 preparations
were of high purity.
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Figure 4.1.  Purity of the HNP-4  preparations.
MALDI-TOF mass spectrometry was used to compare the purity of purified and
synthetic HNP-4 preparations in the molecular weight range from 2,000 to 10,000
Da.  Top: Peptide standards (All-in-1 peptide standards) were used to calibrate the
mass spectrometer.  Middle: Purified HNP-4.  Bottom: Synthetic HNP-4.
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Figure 4.2.  Molecular mass of purified and synthetic HNP-4.
MALDI-TOF mass spectrometry was used to compare the molecular weight of
purified and synthetic HNP-4.  Top: The peptide standard bovine insulin B chain.
Middle: Purified HNP-4. Bottom: Synthetic HNP-4.
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Extinction Coefficient
The amount of light absorbed by a solution of a particular protein depends on the
protein concentration and the amino acid composition of the protein.  Therefore,
measuring the absorbance of a HNP-4 solution provides a way to determine the
protein concentration, whether the HNP-4 has the expected amino acid composition,
and whether the solution contains protein contaminants.
To characterize the 300 µM synthetic HNP-4 solution that was prepared by
dissolving a known weight of HNP-4 in a known volume, the absorbance at 278 nm
was measured and found to be 0.413.  Based on this absorbance, the molar extinction
coefficient of synthetic HNP-4 at 278 nm is 1,377.  This value is close to the value of
1,400 that was calculated for the HNP-4 protein sequence with the on-line Protein
Calculator v3.3 software provided by Chris Putnam of Scripps Research Institute
<www.scripps.edu/~cdputnam/protcalc.html>.  This calculation is based on the
absorption of aromatic amino residues using equations based on the method of Gill
and Von Hippel (58).  The molar extinction coefficient of 1,377 for HNP-4 is much
lower than the value of 9,800 that was calculated for HNP-1 at 278 nm.  HNP-4 has
one uv-absorbing amino acid residue, tyrosine (Y), but HNP-1 has one tryptophan
(W) and three tyrosine (Y) residues.  This observation provides more evidence that
the synthetic HNP-4 had the correct amino acid composition and was of high purity.
Because the volume of the HNP-4 preparation from human neutrophils was small,
it wasn’t possible to determine the extinction coefficient of purified HNP-4.
However, the column fractions that were combined and concentrated to obtain HNP-4
had a low 280 nm absorbance compared with the protein concentration that was
measured for the purified HNP-4.  This result is consistent with isolation of a peptide
with a low extinction coefficient and no contaminating proteins or peptides.
Activity of Synthetic and Purified HNP-4 against E. coli
Killing of E. coli ML-35 by Synthetic HNP-4
The goals of this experiment were to determine whether synthetic HNP-4 kills
E. coli ML-35 and whether very low concentrations of HNP-4 are enough to kill. The
ML-35 strain of E. coli is the standard test organism for measuring alpha-defensin
activity.  These bacteria are killed by human leukocyte defensin HNP-1, -2, or -3 (17).
Washed bacteria (106 CFU/ml) were diluted and plated immediately or incubated
4 h at 37ºC with various concentrations of synthetic HNP-4 from 0 to 30 µM in dilute
growth medium (1% TSB) with 10 mM phosphate buffer.  At the end of the
incubation, the number of viable organisms was determined by diluting, plating, and
counting colonies.
Figure 4.3 shows that when HNP-4 was not added, the bacteria grew during the 4
h incubation.  The number of colony-forming units increased almost 100-fold.
Adding 3 µM HNP-4 partially inhibited growth.  Adding 5 µM HNP-4 blocked
growth and caused about a 90% decrease in the number of viable bacteria below the
starting level of 106 CFU/ml.  Adding 10 µM HNP-4 caused nearly a 100-fold
decrease in the number of viable bacteria, and 30 µM HNP-4 caused a 1000-fold
decrease.  The lowest concentration of HNP-4 that consistently killed about 99% of
the bacteria was 10 µM. This concentration of HNP-4 (10 µM) was chosen as the
concentration to be used in later experiments.
The results show that synthetic HNP-4 killed E. coli ML-35.  However, the
HNP-4 concentration needed was not especially low.  In other experiments (not
shown), purified 5 µM HNP-1 caused 99.7 ± 0.1% killing of E. coli ML-35.
Therefore, HNP-4 was not more active than HNP-1 when tested under these
conditions.  Instead, HNP-4 was about half as active as HNP-1.
Our results with HNP-1 were consistent with results from other laboratories.
Previous studies of the activity of human neutrophil defensins against E. coli used 15
µM HNP-1 or a HNP 1-3 mixture (17), 6 to 9 µM HNP-1 (26), or 7 µM synthetic
HNP-1 (20) to kill 99% of the bacteria.
Killing of E. coli ML-35 by Purified HNP-4
To determine whether HNP-4 purified from human neutrophils is more effective
than synthetic HNP-4, killing of E. coli ML-35 by purified HNP-4 was measured
under the experimental conditions described above.  The experiment was not
performed in duplicate because only a small amount of HNP-4 was available.  The
results with HNP-4 purified from human neutrophils were similar to those with
synthetic HNP-4.  Purified HNP-4 at 1 or 3 µM had no effect, but 10 µM purified
HNP-4 killed 99% of the bacteria (data not shown).  Therefore, when tested under the
same conditions against the standard test gram negative organism, synthetic and
purified HNP-4 had equal activity.
Because very little purified HNP-4 was available, all further experiments were
performed with synthetic HNP-4.
Killing of E. coli Serotype O111:B4 by Synthetic HNP-4
LPS from E. coli serotype O111:B4 is commercially available and has been used
in many published studies of LPS.  Therefore, LPS from E. coli serotype O111:B4
was used in this study as an example of LPS purified from an HNP-4 sensitive
organism.  Experiments similar to those described above were performed to confirm
that E. coli O111:B4 is killed by HNP-4.  Figure 4.4 shows that E. coli serotype
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Figure 4.3.  Synthetic HNP-4 kills E. coli ML-35.
E. coli ML-35 bacteria (106/ml) were incubated 4 h at 37°C without HNP-4 (control;
white bar) or with 0.3 to 30 µM HNP-4 (gray bars). Values shown on the logarithmic
scale in the bar graph are shown in linear form in the table below the graph.
Vi
ab
le
 E
. c
ol
i M
L-
35
 b
ac
te
ria
 (C
FU
/m
L)
HNP-4 (μM)
        0           0.3            1              3              5             10            30
108
107
106
105
104
103
*
*
*
*
54.446
57.189
65.424
32.143
0.122
0.020
0.001
2.615
6.394
3.336
14.008
0.097
0.007
0.000
30
3
7
5
5
26
4
—
1.0
0.6
0.03
<0.0001
<0.0001
<0.0001
Control (4 h, 37°C)
HNP-4, 0.3 µM
HNP-4, 1 µM
HNP-4, 3 µM
HNP-4, 5 µM
HNP-4, 10 µM
HNP-4, 30 µM
Conditions   Viable bacteria  (106 CFU/ml)     S.E.   n   P Value
* Significantly different from the control value without HNP-4.
*
*
*
*
23
Figure 4.4.  Synthetic HNP-4 kills E. coli of serotype O111:B4.
E. coli bacteria (106/ml) of serotype O111:B4 were incubated 4 h at 37°C without
HNP-4 (control; white bar) or with 0.3 to 30 µM HNP-4 (gray bars).
        0              0.3             1                3               10              30
108
107
106
105
104
103
*
*
*
V
ia
bl
e 
E
. c
ol
i O
11
1:
B
4 
ba
ct
er
ia
 (C
FU
/m
L)
HNP-4 (μM)
30.137
29.224
35.616
0.047
0.001
0.002
4.566
0.913
6.393
0.026
0.000
0.001
2
2
2
2
2
2
—
1.0
0.9
0.01
0.01
0.01
Control (4 h, 37°C)
HNP-4, 0.3 µM
HNP-4, 1 µM
HNP-4, 3 µM
HNP-4, 5 µM
HNP-4, 10 µM
* Significantly different from the control value without HNP-4.
*
*
*
Conditions   Viable bacteria  (106 CFU/ml)     S.E.   n   P Value
24
O111:B4 bacteria were killed by HNP-4.  Similar levels of HNP-4 were needed for
killing of E. coli ML-35 (Figure 4.3) or the serotype O111:B4 bacteria (Figure 4.4).
Binding of HNP-4 to E.coli LPS
To determine whether HNP-4 binds to purified E. coli LPS, E. coli ML-35
bacteria (106 CFU/ml) were incubated 4 h at 37°C with 10 µM HNP-4 and various
concentrations of purified E. coli LPS from 0 to 10 µM.  Killing was determined by
diluting, plating, and counting colonies.  The goal was to determine whether the
purified LPS would absorb the HNP-4 and block killing of the bacteria.
Figure 4.5 shows that when no HNP-4 was added, the number of bacteria
increased almost 100-fold.  Incubating with 10 µM LPS did not promote or inhibit
growth.  When 10 µM HNP-4 was added, HNP-4 caused 99.2 ± 0.4% killing.  Adding
LPS from 1 to 5 µM along with HNP-4 caused a concentration-dependent decrease in
killing. With 10 µM HNP-4 and 5 µM LPS, growth was the same as without HNP-4.
The amount of LPS that was needed to block was an LPS to HNP-4 ratio of 1:2.
  The results show that the effect of LPS on killing by HNP-4 was a result of LPS
absorbing HNP-4 and not an effect of LPS on bacterial growth, because LPS had no
effect when LPS was added without HNP-4.
Blocking of HNP-4 Activity by LPS Fragments
The aim of these experiments was to determine whether the oligosaccharide, core,
or lipid A part of LPS is the site where HNP-4 binds.  Chemically-derived LPS
fragments and LPS preparations from E. coli rough mutants were tested for their
ability to absorb HNP-4 and block killing of E. coli.
Role of the Lipid A Part of LPS in HNP-4 Binding
Two approaches were used to determine whether lipid A is the site where HNP-4
binds to LPS.  We tested an LPS fragment that does not have a complete lipid A, and
we tested pure lipid A.
Effect of Deacylated LPS on Killing by HNP-4
The aim of this experiment was to determine whether HNP-4 binds to the
hydrophobic fatty acids of the lipid A part of LPS.  Deacylated-LPS (deacyl-LPS) has
been chemically treated to remove the fatty acids.  If HNP-4 binds to the hydrophobic
part of lipid A, then binding to deacyl-LPS will be weaker than binding to intact LPS.
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Figure 4.5.  E. coli LPS blocks HNP-4 killing of E. coli ML-35.
E. coli ML-35 bacteria (106/ml) with 0 or 10 µM E. coli LPS were incubated 4 h at 37°C,
diluted, and plated (white bars).  Alternatively, the bacteria were incubated with 10 µM
HNP-4 and 0 to 10 µM purified LPS from E. coli of serotype O111:B4 (gray bars).
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E. coli ML-35 bacteria were incubated with 10 µM HNP-4 and various
concentrations of deacyl-LPS.  Figure 4.6 shows that 10 µM deacyl-LPS alone did
not promote or inhibit growth.  HNP-4 (10 µM) killed 96 ± 3 % of the E. coli.
Deacyl-LPS was nearly as effective as intact LPS at blocking HNP-4.  Deacyl-LPS at
5-7 µM or intact LPS at 3-5 µM (Figure 4.5) was needed to block 10 µM HNP-4.
Therefore, the fatty acids of LPS were not required for binding of HNP-4 to LPS.
This result indicates that HNP-4 must bind to some other part of LPS, such as the
oligosaccharide, core, or the part of lipid A that remains when the fatty acids are
removed from LPS.
Effect of Lipid A on Killing by HNP-4
Lipid A contains fatty acids, glucosamine, and phosphate groups.  Phosphate
groups are negatively charged, and HNP-4 has a net positive charge, so phosphate
groups of lipid A might be the site where HNP-4 binds to LPS.  To test the effect of
lipid A, E. coli ML-35 bacteria were incubated with 10 µM HNP-4 and various
concentrations of lipid A, which was solubilized with triethylamine.  In control
experiments (not shown), these low concentrations of triethylamine had no effect on
growth.
Figure 4.7 shows that 20 µM lipid A alone had no effect on growth of the
bacteria.  Lipid A did not block HNP-4 killing even at 2:1 ratio of lipid A to HNP-4,
whereas a 1:2 ratio of LPS to HNP-4 was enough to block killing.  Therefore, HNP-4
does not bind to the lipid A part of LPS.
Role of the LPS Core in HNP-4 Binding
The highly variable oligosaccharide part of LPS is linked to the less-variable LPS
core.  The core can be divided into inner and outer core. The goal of these
experiments was to determine if HNP-4 binds to the LPS core and if so, whether it
binds to the inner or outer core.
Figure 4.8 shows structures of the LPS fragments used in these experiments.
These fragments are from E. coli K12 mutants with defects in LPS synthesis (33,38).
Kdo2-lipid A has only 2 of the 3 Kdo units of the LPS core (59).  Re LPS has 3 Kdo
units and a phosphoryl-ethanolamine group, which is attached to a Kdo unit.  Rc LPS
has the complete inner core with 3 Kdo units, 3 heptose units, pyrophosphoryl-
ethanolamine, phosphoryl-ethanolamine, and a phosphate group.  It also has two
hexose units, galactose and glucose, which are part of the outer core.  Ra LPS has the
complete inner core and the outer core, which is a branched polysaccharide
containing hexoses and one heptose unit.
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Figure 4.6.  Deacyl-LPS blocks HNP-4 killing of E. coli ML-35.
E. coli ML-35 bacteria (106/ml) with 0 or 10 µM deacyl-LPS were incubated 4 h at
37°C and then diluted and plated (white bars).  Alternatively, the bacteria were
incubated with 10 µM HNP-4 and various levels of deacyl-LPS (gray bars).
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Figure 4.7.  Lipid A does not block HNP-4 killing of E. coli ML-35.
E. coli ML-35 bacteria (106/ml) with 0 or 20 µM E. coli lipid A were incubated 4 h at
37°C and then diluted and plated (white bars).  Alternatively, the bacteria were
incubated with 10 µM HNP-4 and various levels of purified E. coli lipid A (gray
bars).
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Figure 4.8.  Structures of Kdo2-lipid A and LPS from rough mutants.
Kdo2-lipid A is an LPS fragment isolated from a rough mutant of E. coli.  LPS from
the Re mutant has the three Kdo units of the inner core, but not the three heptose
units.  The Rc mutant has the complete inner core plus a glucose (Glc) and galactose
(Gal) of the outer core.  The Ra mutant has the complete inner and outer core.
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Re LPS
Rc LPS
Ra LPS
Lipid AKdo
Kdo
Lipid AKdo
Kdo
Kdo
PEtn
Lipid AKdo
Kdo
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Effect of Kdo2-lipid A on Killing by HNP-4
Lipid A is linked to the three Kdo sugar units of the LPS inner core.  The goal of
this experiment was to determine whether HNP-4 binds to Kdo groups attached to
lipid A.  E. coli ML-35 bacteria were incubated with 10 µM HNP-4 and various
concentrations of Kdo2-lipid A.
Figure 4.9 shows that Kdo2-lipid A alone had no effect on growth.  Kdo2-lipid A
partially blocked HNP-4 killing, but a high ratio of Kdo2-lipid A to HNP-4 was
needed (two Kdo2-lipid A to one HNP-4).  These results indicate that HNP-4 binds to
the two Kdo units of Kdo2-lipid A, but binding is not as strong as HNP-4 binding to
LPS.
Effects of Re, Rc, and Ra LPS on Killing by HNP-4
The aim of these experiments was to determine whether HNP-4 binds to LPS
from mutants that have partial or complete LPS cores attached to lipid A.
To test the effect of Re LPS on killing by HNP-4, E. coli ML-35 bacteria were
incubated with 10 µM HNP-4 and various concentrations of Re LPS from E. coli
K12-D31m4.  Figure 4.10 shows that Re LPS alone had no effect on growth of the
bacteria.  Re LPS completely blocked killing by HNP-4 at a ratio of about one Re
LPS to one HNP-4.  This results shows that Re LPS was more effective than Kdo2-
lipid A and suggests that HNP-4 binds to the Kdo units or to the Kdo and phosphoryl-
ethanolamine units of the inner core.
To test the effect of Rc LPS on killing by HNP-4, E. coli ML-35 bacteria were
incubated with 10 µM HNP-4 and various concentrations of Rc LPS from E. coli J5.
Figure 4.11 shows that 10 µM Rc LPS alone had no effect on growth of the bacteria.
Rc LPS was able to completely block killing at a ratio of about one Rc LPS to two
HNP-4.  Therefore, Rc LPS was more effective than Re LPS, indicating that HNP-4
binding to the complete inner core of LPS with heptoses and an additional phosphate
and diphosphoryl-ethanolamine moiety was stronger than binding to the Kdo units
and one phosphoryl-ethanolamine.
To test the effect of Ra LPS on killing by HNP-4, E. coli ML-35 bacteria were
incubated with 10 µM HNP-4 and various concentrations of Ra LPS from E. coli
EH100.  Figure 4.12 shows that Ra LPS alone had no effect on growth of the
bacteria.  Ra LPS was able to block killing completely at a ratio of about one Ra LPS
to two HNP-4.  Therefore, Ra LPS was equal to Rc LPS, indicating that adding the
hexose groups of the outer core did not promote HNP-4 binding.  In fact, Rc LPS was
as effective as intact LPS.
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Figure 4.9.  Kdo2-lipid A blocks HNP-4 killing of E. coli ML-35.
E. coli ML-35 bacteria (106/ml) with 0 or 20 µM Kdo2-lipid A were incubated 4 h at
37°C and then diluted and plated (white bars).  Alternatively, the bacteria were
incubated with 10 µM HNP-4 and various levels of purified Kdo2-lipid A (gray bars).
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Figure 4.10.  Rough (Re) LPS blocks HNP-4 killing of E. coli ML-35.
E. coli ML-35 bacteria (106/ml) with 0 or 10 µM rough (Re) E. coli LPS were
incubated 4 h at 37°C and then diluted and plated (white bars).  Alternatively, the
bacteria were incubated with 10 µM HNP-4 and various levels of rough (Re) LPS
from E. coli K12-D31m4 (gray bars).
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Figure 4.11.  Rough (Rc) LPS blocks HNP-4 killing of E. coli ML-35.
E. coli ML-35 bacteria (106/ml) with 0 or 10 µM rough (Rc) E. coli LPS were
incubated 4 h at 37°C and then diluted and plated (white bars).  Alternatively, the
bacteria were incubated with 10 µM HNP-4 and various levels of purified rough (Rc)
LPS from E. coli J5 (gray bars).
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Figure 4.12.  Rough (Ra) LPS blocks HNP-4 killing of E. coli ML-35.
E. coli ML-35 bacteria (106/ml) with 0 or 10 µM rough (Ra) E. coli LPS were
incubated 4 h at 37°C and then diluted and plated (white bars).  Alternatively, the
bacteria were incubated with 10 µM HNP-4 and various levels of purified rough (Ra)
LPS from E. coli EH100 (gray bars).
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Killing of E. coli J5 by HNP-4
If HNP-4 binds to the inner core of LPS, then HNP-4 should kill the Rc mutant
E. coli J5.  Rc mutants lack the oligosaccharide part of LPS and most of the outer
core and might be more sensitive than E. coli ML-35 to killing by HNP-4. The aim of
this experiment was to determine whether HNP-4 has strong activity against an Rc
mutant.  Bacteria (106 CFU/mL) were incubated 4 h at 37º with various
concentrations of HNP-4.  Figure 4.13 shows that 5 µM HNP-4 killed 99% of the
bacteria.  In results shown earlier (Figure 4.3), 10 µM HNP-4 was needed to kill 99%
of the E. coli ML-35 bacteria.  Therefore, E. coli J5, an Rc mutant that lacks
oligosaccharide and most of the outer core, is killed by HNP-4 and is about twice as
sensitive as E. coli ML-35 to killing by HNP-4.
In other experiments (not shown), E. coli J5 was found to be less sensitive to
killing by HNP-1 than E. coli ML-35.  HNP-1 at 5 µM killed 99% of E. coli ML-35,
but 10 µM HNP-1 was needed for 99% killing of E. coli J5.
Activity of HNP-4 against A.a.
Periodontal pathogens such as A.a. are resistant to killing by HNP-1, -2 or -3 (26).
The goal of these experiments was to determine whether A.a. is also resistant to
HNP-4, or whether HNP-4 is more effective than other alpha-defensins against this
gram-negative organism.
To determine whether A.a. is resistant to HNP-4, A.a. Y4 bacteria (106 CFU/ml)
in dilute growth medium (1% TSB) with 10 mM phosphate pH 7.4 buffer were
diluted and plated immediately, or incubated 4 h at 37°C with 0 to 30 µM HNP-4 or
3 µM polymyxin B.  Incubations were carried out in 96 well plates in an atmosphere
with low O2 and elevated (5-10%) CO2 generated inside a BBL™ GasPak Pouch™
Anaerobic System.  At the end of the incubation, the number of viable bacteria was
determined by diluting, plating, and counting colonies.
Figure 4.14 shows that A.a. grew slowly, resulting in about a 10-fold increase in
the number of viable bacteria rather than the 100-fold increase seen in experiments
with E. coli.  HNP-4 at concentrations up to 30 µM did not kill A.a. Y4.  There was
partial inhibition of growth, but inhibition did not increase with increasing
concentrations of HNP-4.  In contrast, the gram-negative specific antibiotic
polymyxin B at 3 µM killed > 99.9 % of the A.a. bacteria (not shown), confirming
that the bacteria could be killed under these experimental conditions. The results
indicate that A.a. Y4 is highly resistant to HNP-4.
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Figure 4.13.  HNP-4 kills rough (Rc) E. coli J5.
E. coli J5 bacteria (106/ml) were incubated 4 h at 37°C without HNP-4 (control;
white bar) or with 0.3 to 10 µM HNP-4 (gray bars).
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Figure 4.14.  HNP-4 inhibits A.a. growth.
A.a. Y4 bacteria (106/ml) were incubated 4 h at 37°C without HNP-4 (control; white
bar) or with 0.3 to 30 µM HNP-4 (gray bars).
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Binding of HNP-4 to A.a. LPS
The aim of these experiments was to determine whether HNP-4 is unable to kill
A.a. because LPS on the surface of A.a. can’t act as a receptor for HNP-4.  E. coli
ML-35 (106 CFU/mL), 10 µM HNP-4, and various concentrations of LPS purified
from the Y4 strain of A.a. were diluted and plated immediately or incubated 4 h at
37°C.
If HNP-4 can’t bind to A.a. LPS, then A.a. LPS should not absorb HNP-4 and
block killing of E. coli.  Figure 4.15 shows that in the absence of HNP-4 the E. coli
grew and increased in number nearly 100-fold.  Adding purified A.a. LPS did not
promote or inhibit the growth of E. coli.  HNP-4 at 10 µM killed 94 ± 3% of the
E. coli.  Purified A.a. LPS (3 to 5 µM) blocked the action of 10 µM HNP-4.
Therefore, A.a. LPS was as effective as E. coli LPS in binding HNP-4 and blocking
killing.
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Figure 4.15.  A.a. LPS blocks HNP-4 killing of E. coli ML-35.
E. coli ML-35 bacteria (106/ml) with 0 or 10 µM A.a. Y4 LPS were incubated 4 h at
37°C and then diluted and plated (white bars).  Alternatively, the bacteria were
incubated with 10 µM HNP-4 and various levels of purified A.a. LPS (gray bars).
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CHAPTER 5.  DISCUSSION
Physical Properties of Synthetic and Purified HNP-4
Our laboratory was in a unique position to compare antibacterial activity of
synthetic and purified HNP-4 because we had access to both.  Our results show that
both the synthetic and purified HNP-4 preparations had high purity.  No other
peptides or proteins were detected by mass spectrometry.  Both preparations also
appeared identical.  They had the same molecular weight, which is the same as the
molecular weight calculated from the published amino acid sequence of HNP-4.
They also had the same low extinction coefficient expected for a peptide with one
tyrosine residue.
Therefore, the activity of synthetic and purified HNP-4 should be the same.  If
there is any difference in activity, it must be due to something that could not be
detected with the methods we used.  For example, the molecular weight we measured
is consistent with formation of three disulfide bonds by the 6 cysteines, but we would
not be able to detect if the bonds were all paired correctly (1 to 6, 2 to 4, and 3 to 5).
Synthetic HNP-4 is easier to obtain than purified HNP-4.  Further studies will
probably use synthetic HNP-4.  Synthetic HNP-4 would also be more convenient for
clinical applications, and there would be no concern about possible contamination by
viruses or prions from human blood.
Activity of Synthetic and Purified HNP-4 against the Standard Test Organism
Our experiments showed no difference in the activity of synthetic and purified
HNP-4 when tested under the same conditions against the standard gram-negative test
organism E. coli ML-35.  Synthetic or purified HNP-4 had about the same activity as
HNP-1.  Our results do not support the conclusion that HNP-4 is more active than
other alpha-defensins against gram-negative bacteria.
Although HNP-4 has a much different sequence than the other alpha-defensins,
the difference does not have a large effect on activity against E. coli ML-35.
Therefore, HNP-4 does not seem to have a special role in helping neutrophils kill
gram-negative bacteria.
Binding of HNP-4 to E. coli LPS
The results of our experiments showed that purified E. coli LPS is able to absorb
HNP-4 and block its activity.  A ratio of about one LPS to two HNP-4 was enough to
block activity.  Therefore, HNP-4 binds to LPS from bacteria that are killed by HNP-4.
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The 1:2 ratio of LPS to HNP-4 could indicate that two molecules of HNP-4 form
a dimer in solution, and that one HNP-4 dimer binds to one LPS molecule.  A recent
article reported that HNP-4 forms a dimer (21).  The 1:2 ratio could also indicate that
there are multiple binding sites for HNP-4 on LPS.  Two HNP-4 monomers might
bind at the same time to different sites on LPS.  But it is not certain that the 1:2 ratio
of blocking indicates a binding ratio.  Our approach to detecting binding by
measuring blocking of HNP-4 activity is very indirect.  Other methods are needed to
measure HNP-4 binding to LPS.
LPS as the Receptor for HNP-4
Our results show that purified lipid A did not absorb HNP-4 and block killing by
HNP-4.  Although lipid A has two negatively-charged phosphate groups, the cationic
HNP-4 did not bind strongly to these anionic groups.  We also found that LPS with
the fatty acids removed from lipid A blocked as well as intact LPS.  These results rule
out lipid A as the binding site for HNP-4.
Table 5.1 summarizes results that indicates that the LPS inner core is the site
where HNP-4 binds.  Ra LPS with no oligosaccharide blocked as well as LPS.
These results rule out oligosaccharide as the binding site for HNP-4.  Rc LPS
with a complete inner core but only part of the outer core blocked as well as Ra LPS,
which has a complete inner and outer core.  The outer core or the outer core plus
oligosaccharide were not needed to absorb HNP-4 and block killing.
The inner core of LPS (which includes Kdo units, heptoses, phosphate, and
phosphoryl- and pyrophosphoryl-ethanolamine groups) may be the HNP-4
binding site.  Binding of HNP-4 to the inner core of LPS can account for all of the
ability of LPS or LPS fragments to block HNP-4 activity.  These results suggest that
the LPS inner core is the binding site for HNP-4 on the surface of gram-negative
bacteria.
Our experiments found that the Rc mutant E. coli J5 was more sensitive than
E. coli ML-35 to killing by HNP-4.  In other experiments (not shown), E. coli J5 was
found to be less sensitive to killing by HNP-1 than E. coli ML-35.  HNP-1 at 5 µM
killed 99% of E. coli ML-35 and 10 µM was needed for 99% killing of E. coli J5.
Although the results need to be confirmed with side by side testing of HNP-1
and HNP-4 within the same experiment, these results suggest that HNP-1 is more
effective against wild-type organisms, and HNP-4 is more effective against
rough strains that have a complete inner core but lack the outer core and
oligosaccharide.
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Table 5.1.  Concentrations of LPS or LPS fragments that block 10 μM HNP-4.
LPS or fragment
LPS (O111:B4)
Rough (Ra) LPS
Rough (Rc) LPS
Rough (Re) LPS
Kdo2-lipid A
Lipid A
Blocking concentration (μM)
      5
      5
      5
    10
    20
           >>20
Recent studies show that HNP-1, -2, and -3 have a lectin-like ability to bind to the
carbohydrate part of glycoproteins (7,60).  Binding to glycoproteins on the surface of
virus particles contributes to the ability of alpha-defensins to interfere with infection
by herpes simplex virus (HSV) and human immunodeficiency virus-1 (HIV-1).
HNP-4 was reported to not have lectin activity, but HNP-4 was more effective than
HNP 1-3 in blocking HIV-1 infection (61).  Binding of HNP-4 to heparan sulfate,
which is a receptor for the HSV virus on human cells, was reported to contribute to
antiviral activity.  Heparin sulfate is a polysaccharide with many negative charges,
which could attract the positively-charged HNP-4.
Our results suggest that HNP-4 may have lectin-like activity, because it binds to
the Kdo units of Kdo2-lipid A.  It binds stronger to Re LPS, which has three Kdo
units, and binds even stronger to Rc LPS, which has heptose units in addition to Kdo
units.  On the other hand, negative charges on the inner core may account for binding
of the cationic HNP-4.  Each Kdo unit has a negative charge, and the phosphate,
phosphoryl, and pyrophosphoryl units have negative charges.  Therefore, binding of
HNP-4 to the inner core could be explained by binding of positive to negative
charges rather than binding of HNP-4 to specific sugars such as Kdo or heptose.
Activity of HNP-4 against A.a.
Our results showed that HNP-4 was similar to HNP-1 in having little or no
activity against A.a.  HNP-4 did not kill A.a.  HNP-4 was able to partially inhibit
growth, but inhibition did not increase as the HNP-4 concentration increased.  This
leads us to believe that A.a. is resistant in vitro to all the human leukocyte alpha-
defensins including HNP-4.
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If HNP-4 was especially active against all gram-negative bacteria including A.a.
and other periodontal pathogens, then the results would raise a question of how the
bacteria can survive in periodontal pockets in contact with neutrophils and defensins.
The amount of HNP-4 in neutrophils may be too small to control the periodontal
pathogens in vivo.  However, the results seem to indicate that periodontal pathogens
survive and cause disease because they are resistant to all of the alpha-defensins.
Synthetic HNP-4 does not seem to have the potential for clinical use to prevent or
treat periodontal disease.  Other agents such as protegrins or even polymyxin B might
have greater potential.  However, it is important to note that our experiments tested
only one strain of one periodontal pathogen.  We would need to test HNP-4 against a
broader assortment of bacteria before concluding that HNP-4 is not effective against
periodontal pathogens.
Binding of HNP-4 to A.a. LPS
LPS preparations purified from E. coli and A.a. were identical in their ability to
block HNP-4.  Both showed the same blocking ratio of one LPS to two HNP-4.
Therefore, A.a. resistance to HNP-4 is not a result of failure of HNP-4 to bind to A.a.
LPS.  Something else must explain resistance of A.a. and probably other periodontal
pathogens to HNP-4.
There are four general mechanisms of antibiotic resistance (62-64):  (a) The
micro-organism is able to destroy or inactivate the antibiotic; (b) The antibiotic does
not get through the outer layers of the cell; (c) The antibiotic gets into the cell but is
pumped back out;  (d) The micro-organism is able to avoid effects of the antibiotic by
using a different metabolic pathway that is not blocked by the antibiotic.
A.a. may produce a factor that destroys or inactivates HNP-4 and other alpha-
defensins.  There could be an enzyme such as a protease that attacks defensins and is
released from the bacteria or located in the cell envelope.  It’s also possible that
HNP-4 binds to LPS on the surface but can’t get through the outer membrane,
peptidoglycan layer, and periplasm to get to the inner membrane.
HNP-4 and other CAPs probably do not have to get into the cytoplasm of bacteria
in order to have antibacterial activity.  Damage at the inner membrane accounts for
killing of gram-negative bacteria by alpha-defensins (65,66).  Therefore, pumping
HNP-4 out of the bacteria is probably not an important mechanism of resistance.
It’s also unlikely that bacteria could survive an attack by HNP-4 on the inner
membrane.  There’s no alternative pathway that the bacteria can use to make energy
to grow and multiply if their inner membranes are leaky.  Further studies are needed
to determine the mechanism of resistance of periodontal pathogens to human
leukocyte alpha-defensins.
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